3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Injections
98
pembrolizumab
90
Carboplatin
57
Paclitaxel
54
Cisplatin
52
Nivolumab
44
Docetaxel
43
Pemetrexed
42
Gemcitabine
37
atezolizumab
32
tislelizumab
29
Bevacizumab
29
toripalimab
23
Fluorouracil
23
Capecitabine
23
Irinotecan
22
Oxaliplatin
20
durvalumab
19
Ipilimumab
18
Leucovorin
17
Cetuximab
17
Rifampin
14
Itraconazole
14
olaparib
13
spartalizumab
12
Midazolam
12
Cyclophosphamide
12
trifluridine tipiracil drug combination
11
sintilimab
11
Drug Therapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Blood Component Removal
×
Other solid neoplasm
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled